{"id":"resorcinol","brandName":"resorcinol","genericName":"resorcinol","companyId":"unknown","companyName":"","phase":"unknown","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Resorcinol is a small molecule organic compound with the formula C6H4(OH)2, classified as a phenolic compound and one of three isomeric benzenediols. It is used in a 0.2% concentration in a cream as an intervention in clinical trials for conditions such as wrinkles, facial hyperpigmentation, melasma, and hydradenitis.","enrichmentLevel":3,"visitCount":0,"mechanism":{"target":"Carbonic anhydrase 12, Carbonic anhydrase 14, Carbonic anhydrase 2"},"administration":{},"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Anemia due to enzyme deficiency","Blister","Conduction disorder of the heart","Condyloma acuminatum","Decreased respiratory function","Deficiency of cytochrome-b>5< reductase","Deficiency of glucose-6-phosphate dehydrogenase","Denuded skin","Diabetes mellitus","Eruption of skin","Folliculitis","Infection of skin AND/OR subcutaneous tissue","Inflammatory dermatosis","Kidney disease","Methemoglobinemia","Open wound","Peripheral vascular disease","Seizure disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":["NCT03826277","NCT04099212","NCT01586819","NCT04429308","NCT03926845","NCT06516224"],"indications":{"approved":[{"name":"Acne vulgaris","diseaseId":"acne-vulgaris","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acneiform eruption","diseaseId":"acneiform-eruption","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Itching of skin","diseaseId":"itching-of-skin","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Minor Skin Wound Pain","diseaseId":"minor-skin-wound-pain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Skin irritation","diseaseId":"skin-irritation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT03826277","phase":"NA","title":"The Efficacy of Melanostop Peel in Combination With Specifically Selected Home Care Regimen for Improvement of Melasma","status":"UNKNOWN","sponsor":"VIST - Faculty of Applied Sciences","isPivotal":false,"enrollment":10,"indication":"Melasma","completionDate":"2024-12"},{"nctId":"NCT04099212","phase":"N/A","title":"OBSERVATIONAL CASE-ONLY PROSPECTIVE STUDY OF EFFECTIVENESS AND SAFETY OF 15% TOPICAL RESORCINOL FOR ADULTS WITH HURLEY I-II HIDRADENITIS SUPPURATIVA.","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","isPivotal":false,"enrollment":40,"indication":"HYDRADENITIS","completionDate":"2020-08-30"},{"nctId":"NCT01586819","phase":"Phase 3","title":"Treatment of Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A: A Split-face, Rater-blinded Randomized Control Trial","status":"COMPLETED","sponsor":"Loyola University","isPivotal":true,"enrollment":26,"indication":"Wrinkles","completionDate":"2013-05"},{"nctId":"NCT04429308","phase":"Phase 2","title":"PDT Versus the Combination of Jessner's Solution and 35% TCA for Treatment of Actinic Keratoses on Upper Extremities: A Randomized Controlled Split-arm Trial","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","isPivotal":false,"enrollment":60,"indication":"Actinic Keratoses","completionDate":"2026-12"},{"nctId":"NCT03926845","phase":"NA","title":"Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation, A Randomized Double-blind and Vehicle-Controlled Study","status":"COMPLETED","sponsor":"Institute of Dermatology, Thailand","isPivotal":false,"enrollment":200,"indication":"Facial Hyperpigmentation","completionDate":"2021-01-31"},{"nctId":"NCT06516224","phase":"NA","title":"Evaluation of the Efficacy of the Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma","status":"NOT_YET_RECRUITING","sponsor":"Cosmetique Active International","isPivotal":false,"enrollment":150,"indication":"Melasma","completionDate":"2025-01-31"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}